Adult Preventable Vaccines Industry Research Report 2025

Summary

According to APO Research, the global Adult Preventable Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Adult Preventable Vaccines include Sanofi Pasteur, Johnson & Johnson (Janssen), Pfizer Inc., GlaxoSmithKline plc (GSK), Sinovac Biotech, Sinopharm Group Co.,, Serum Institute of India Pvt., Novavax, Inc. and Moderna, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Adult Preventable Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adult Preventable Vaccines.

The report will help the Adult Preventable Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Adult Preventable Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adult Preventable Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Adult Preventable Vaccines Segment by Company

Sanofi Pasteur
Johnson & Johnson (Janssen)
Pfizer Inc.
GlaxoSmithKline plc (GSK)
Sinovac Biotech
Sinopharm Group Co.,
Serum Institute of India Pvt.
Novavax, Inc.
Moderna, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Daiichi Sankyo Company
CSL Limited (Seqirus)
Bharat Biotech International
AstraZeneca plc
Adult Preventable Vaccines Segment by Type

Viral Vector Vaccines
Peptide Vaccines
Inactivated Vaccines
Subunit Vaccines
Mrna Vaccines
Adult Preventable Vaccines Segment by Application

Prevent Herpes Zoster
Prevent Pneumococcal Infection
Prevent Influenza
Prevent Human Papillomavirus (Hpv)
Prevent Hepatitis B
Other
Adult Preventable Vaccines Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East Middle East & Africa
Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult Preventable Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adult Preventable Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult Preventable Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Adult Preventable Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Adult Preventable Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Adult Preventable Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Adult Preventable Vaccines Market Size (2020-2031)
2.2.2 Global Adult Preventable Vaccines Sales (2020-2031)
2.2.3 Global Adult Preventable Vaccines Market Average Price (2020-2031)
2.3 Adult Preventable Vaccines by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Viral Vector Vaccines
2.3.3 Peptide Vaccines
2.3.4 Inactivated Vaccines
2.3.5 Subunit Vaccines
2.3.6 Mrna Vaccines
2.4 Adult Preventable Vaccines by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Prevent Herpes Zoster
2.4.3 Prevent Pneumococcal Infection
2.4.4 Prevent Influenza
2.4.5 Prevent Human Papillomavirus (Hpv)
2.4.6 Prevent Hepatitis B
2.4.7 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Adult Preventable Vaccines Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Adult Preventable Vaccines Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Adult Preventable Vaccines Revenue of Manufacturers (2020-2025)
3.4 Global Adult Preventable Vaccines Average Price by Manufacturers (2020-2025)
3.5 Global Adult Preventable Vaccines Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Adult Preventable Vaccines, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Adult Preventable Vaccines, Product Type & Application
3.8 Global Manufacturers of Adult Preventable Vaccines, Established Date
3.9 Global Adult Preventable Vaccines Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sanofi Pasteur
4.1.1 Sanofi Pasteur Company Information
4.1.2 Sanofi Pasteur Business Overview
4.1.3 Sanofi Pasteur Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Sanofi Pasteur Adult Preventable Vaccines Product Portfolio
4.1.5 Sanofi Pasteur Recent Developments
4.2 Johnson & Johnson (Janssen)
4.2.1 Johnson & Johnson (Janssen) Company Information
4.2.2 Johnson & Johnson (Janssen) Business Overview
4.2.3 Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio
4.2.5 Johnson & Johnson (Janssen) Recent Developments
4.3 Pfizer Inc.
4.3.1 Pfizer Inc. Company Information
4.3.2 Pfizer Inc. Business Overview
4.3.3 Pfizer Inc. Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Pfizer Inc. Adult Preventable Vaccines Product Portfolio
4.3.5 Pfizer Inc. Recent Developments
4.4 GlaxoSmithKline plc (GSK)
4.4.1 GlaxoSmithKline plc (GSK) Company Information
4.4.2 GlaxoSmithKline plc (GSK) Business Overview
4.4.3 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.4.4 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio
4.4.5 GlaxoSmithKline plc (GSK) Recent Developments
4.5 Sinovac Biotech
4.5.1 Sinovac Biotech Company Information
4.5.2 Sinovac Biotech Business Overview
4.5.3 Sinovac Biotech Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Sinovac Biotech Adult Preventable Vaccines Product Portfolio
4.5.5 Sinovac Biotech Recent Developments
4.6 Sinopharm Group Co.,
4.6.1 Sinopharm Group Co., Company Information
4.6.2 Sinopharm Group Co., Business Overview
4.6.3 Sinopharm Group Co., Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio
4.6.5 Sinopharm Group Co., Recent Developments
4.7 Serum Institute of India Pvt.
4.7.1 Serum Institute of India Pvt. Company Information
4.7.2 Serum Institute of India Pvt. Business Overview
4.7.3 Serum Institute of India Pvt. Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio
4.7.5 Serum Institute of India Pvt. Recent Developments
4.8 Novavax, Inc.
4.8.1 Novavax, Inc. Company Information
4.8.2 Novavax, Inc. Business Overview
4.8.3 Novavax, Inc. Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Novavax, Inc. Adult Preventable Vaccines Product Portfolio
4.8.5 Novavax, Inc. Recent Developments
4.9 Moderna, Inc.
4.9.1 Moderna, Inc. Company Information
4.9.2 Moderna, Inc. Business Overview
4.9.3 Moderna, Inc. Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Moderna, Inc. Adult Preventable Vaccines Product Portfolio
4.9.5 Moderna, Inc. Recent Developments
4.10 Merck & Co., Inc.
4.10.1 Merck & Co., Inc. Company Information
4.10.2 Merck & Co., Inc. Business Overview
4.10.3 Merck & Co., Inc. Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio
4.10.5 Merck & Co., Inc. Recent Developments
4.11 Emergent BioSolutions Inc.
4.11.1 Emergent BioSolutions Inc. Company Information
4.11.2 Emergent BioSolutions Inc. Business Overview
4.11.3 Emergent BioSolutions Inc. Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio
4.11.5 Emergent BioSolutions Inc. Recent Developments
4.12 Daiichi Sankyo Company
4.12.1 Daiichi Sankyo Company Company Information
4.12.2 Daiichi Sankyo Company Business Overview
4.12.3 Daiichi Sankyo Company Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio
4.12.5 Daiichi Sankyo Company Recent Developments
4.13 CSL Limited (Seqirus)
4.13.1 CSL Limited (Seqirus) Company Information
4.13.2 CSL Limited (Seqirus) Business Overview
4.13.3 CSL Limited (Seqirus) Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.13.4 CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio
4.13.5 CSL Limited (Seqirus) Recent Developments
4.14 Bharat Biotech International
4.14.1 Bharat Biotech International Company Information
4.14.2 Bharat Biotech International Business Overview
4.14.3 Bharat Biotech International Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Bharat Biotech International Adult Preventable Vaccines Product Portfolio
4.14.5 Bharat Biotech International Recent Developments
4.15 AstraZeneca plc
4.15.1 AstraZeneca plc Company Information
4.15.2 AstraZeneca plc Business Overview
4.15.3 AstraZeneca plc Adult Preventable Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.15.4 AstraZeneca plc Adult Preventable Vaccines Product Portfolio
4.15.5 AstraZeneca plc Recent Developments
5 Global Adult Preventable Vaccines Market Scenario by Region
5.1 Global Adult Preventable Vaccines Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Adult Preventable Vaccines Sales by Region: 2020-2031
5.2.1 Global Adult Preventable Vaccines Sales by Region: 2020-2025
5.2.2 Global Adult Preventable Vaccines Sales by Region: 2026-2031
5.3 Global Adult Preventable Vaccines Revenue by Region: 2020-2031
5.3.1 Global Adult Preventable Vaccines Revenue by Region: 2020-2025
5.3.2 Global Adult Preventable Vaccines Revenue by Region: 2026-2031
5.4 North America Adult Preventable Vaccines Market Facts & Figures by Country
5.4.1 North America Adult Preventable Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Adult Preventable Vaccines Sales by Country (2020-2031)
5.4.3 North America Adult Preventable Vaccines Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Adult Preventable Vaccines Market Facts & Figures by Country
5.5.1 Europe Adult Preventable Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Adult Preventable Vaccines Sales by Country (2020-2031)
5.5.3 Europe Adult Preventable Vaccines Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Adult Preventable Vaccines Market Facts & Figures by Country
5.6.1 Asia Pacific Adult Preventable Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Adult Preventable Vaccines Sales by Country (2020-2031)
5.6.3 Asia Pacific Adult Preventable Vaccines Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Adult Preventable Vaccines Market Facts & Figures by Country
5.7.1 South America Adult Preventable Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Adult Preventable Vaccines Sales by Country (2020-2031)
5.7.3 South America Adult Preventable Vaccines Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Adult Preventable Vaccines Market Facts & Figures by Country
5.8.1 Middle East and Africa Adult Preventable Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Adult Preventable Vaccines Sales by Country (2020-2031)
5.8.3 Middle East and Africa Adult Preventable Vaccines Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Adult Preventable Vaccines Sales by Type (2020-2031)
6.1.1 Global Adult Preventable Vaccines Sales by Type (2020-2031) & (K Units)
6.1.2 Global Adult Preventable Vaccines Sales Market Share by Type (2020-2031)
6.2 Global Adult Preventable Vaccines Revenue by Type (2020-2031)
6.2.1 Global Adult Preventable Vaccines Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Adult Preventable Vaccines Revenue Market Share by Type (2020-2031)
6.3 Global Adult Preventable Vaccines Price by Type (2020-2031)
7 Segment by Application
7.1 Global Adult Preventable Vaccines Sales by Application (2020-2031)
7.1.1 Global Adult Preventable Vaccines Sales by Application (2020-2031) & (K Units)
7.1.2 Global Adult Preventable Vaccines Sales Market Share by Application (2020-2031)
7.2 Global Adult Preventable Vaccines Revenue by Application (2020-2031)
7.2.1 Global Adult Preventable Vaccines Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Adult Preventable Vaccines Revenue Market Share by Application (2020-2031)
7.3 Global Adult Preventable Vaccines Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Adult Preventable Vaccines Value Chain Analysis
8.1.1 Adult Preventable Vaccines Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Adult Preventable Vaccines Production Mode & Process
8.2 Adult Preventable Vaccines Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Adult Preventable Vaccines Distributors
8.2.3 Adult Preventable Vaccines Customers
9 Global Adult Preventable Vaccines Analyzing Market Dynamics
9.1 Adult Preventable Vaccines Industry Trends
9.2 Adult Preventable Vaccines Industry Drivers
9.3 Adult Preventable Vaccines Industry Opportunities and Challenges
9.4 Adult Preventable Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings